• Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub
  •  0 items - £0.00
  • Menu
  • Skip to right header navigation
  • Skip to main content
  • Skip to secondary navigation
  • Skip to primary sidebar
  • Skip to footer

Before Header

  • My account
  •  0 items - £0.00

Action Duchenne

Header Right

  • Donate
  • About Us
    • Marking 25 Years of Action Duchenne
    • Our Purpose
    • What We Do
    • Our Impact
    • Our Team
    • Work For Us
    • Volunteer
    • The DMD Registry
    • Action Duchenne Policies
  • Get Support
    • Register for Support
      • Time Out – A Space for Mums
      • Dads Against Duchenne
      • Grandparents Together
    • Recently diagnosed
    • Children and Young People
    • Schools
    • End of Life and Bereavement
  • Community Summit
    • Action Duchenne Community Summit 2026
    • Community Summit 2026 Agenda and Sponsors
    • Highlights from the Action Duchenne Conference 2025
  • News, Webinars and Blogs
    • News
    • Webinar Series 2026
    • Webinar recordings
    • Bite-Sized Duchenne Science Live
      • Facts about Duchenne muscular dystrophy
      • Signs and Symptoms of Duchenne Muscular Dystrophy
      • Diagnosis of Duchenne Muscular Dystrophy
      • Crucial Genetic Terminology
      • Genetics – Blueprint of Duchenne Muscular Dystrophy
      • How is Duchenne Muscular Dystrophy Inherited?
    • Hear From Our Community
  • Support Us
    • Friends of Action Duchenne
    • COMMUNITY BUSINESS PARTNERS: Creating Lasting Impact for Families Living with Duchenne
    • Side by Side: Running Together for Action Duchenne – Your Invitation
    • Upcoming Events and Challenges
    • Give in memory and help us support every family, every time.
    • You Do YOU – Fundraise Your Way
    • Fundraising at school
    • Donate by cheque and post
    • Welcome to our Runner Hub

Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

You are here: Home / News / Gene therapy / Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy

23 June 2023 by Mehreen Arif

Sarepta Therapeutics announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. ELEVIDYS is a one-time treatment designed to treat the underlying genetic cause of Duchenne.


“The approval of ELEVIDYS is a watershed moment for the treatment of Duchenne. ELEVIDYS is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” said Doug Ingram, president and chief executive officer, Sarepta. “As we prepare to launch ELEVIDYS, we should acknowledge and celebrate the decades of dedication and work from the patient community, families, clinicians, and our Sarepta colleagues that resulted in today’s approval. Our confirmatory trial, EMBARK, should read out in the fourth quarter of this year. If EMBARK confirms the benefits seen in our prior trials, Sarepta will move rapidly to submit a BLA supplement to expand the approved label as broadly as good science permits.”

Please see the full press release here

Do you want to know more?

  • To find out more about Duchenne science, gain crucial knowledge and support, please join us on our Science on Tour workshops. We are coming to 30 locations across the UK in 2023 – book your FREE place here now. 
  • SAVE THE DATE: Action Duchenne’s International Conference 2023 will be held on the 10th and 11th November and is an amazing opportunity to meet with those involved in every aspect of Duchenne, from families, clinicians, researchers and pharmaceutical companies. 

Share this:

Category: Gene therapy, News

Previous Post: « Join National Director Florence Boulton as part of our Vitality London 10,000 Team!
Next Post: Roche UK issues a statement following Sarepta’s Press release regarding ELEVIDYS FDA decision »

Primary Sidebar

From our community

From receiving support to giving it back: Nicola’s journey with Action Duchenne

Written by Nicola Culverhouse “If you had told me two years ago that I would be volunteering for Action Duchenne, I wouldn’t have believed you. Our four-year-old son, Kitto, was diagnosed with Duchenne in August 2024, following 12 months of infections and investigations. He had met all his milestones and we had absolutely no concerns …

Action Duchenne Residential Weekends: “Adventure is still possible”

Action Duchenne Residential Weekends: “Adventure is still possible“ With a Duchenne diagnosis, it often feels that there is an ever-growing list of things that become more difficult. The freedom to choose to take part in activities, to continue hobbies or even just to pop round to a friend’s house changes into something that needs planning, …

Honouring George and Finding Community

Honouring George and Finding Community Remembering George one year on. “If I’d never experienced George having Duchenne, I wouldn’t be half the person I am now. He taught me so much about life. I truly believe that boys with Duchenne are just the most awesome people in the world.”  On Sunday 26th April 2026, Louise Ruddick ran the …

Footer

Action Duchenne
2nd Floor
South
One Castle Park
Tower Hill
Bristol
BS2 OJA

0300 102 1762
info@actionduchenne.org 

 

 

 

 

 

 

 

 

Subscribe to our mailing list

Do you consent to receiving regular email updates? *
Email Format
  • Accessibility
  • Privacy Policy
  • Terms & Conditions

Site Footer

Fundraising Regulator badge with validation link

© Action Duchenne - Registered Charity No 1101971 - Scottish Charity No SC043852